Starting glargine in insulin-naïve type 2 diabetic patients based on body mass index is safe

Table 1 Characteristics of the patient population, as grouped according to the four algorithms

	n	Gender	Age (yr)	Weight (kg)	BMI (kg/m2)	Duration (yr)	Baseline A1C	Baseline FPG (mg/dL)	Previous treatment
Fixed titration 2/2 U
LANMET	26	8 M	55.0 ± 10	78 ± 16.6	30.7 ± 4.95	8 ± 4.23	9.39% ± 1.67%	193.0 ± 59.4	2 OAD (20) 1 OAD (6)
Variable titration
LANMET PLUS	22	6 M	52.3 ± 7.7	70.6 ± 13	27.8 ± 4.7	7.8 ± 3.8	9.35% ± 1.34%	179.4 ± 51.4	2 OAD (21) 1 OAD (1)
Fixed titration 2/2 U
DeGold	23	14 M	54.6 ± 8	78.3 ± 13.5	28.8 ± 4.4	10.2 ± 7.1	9.21% ± 1.30%	196.6 ± 54.8	2 OAD (19) 1 OAD (4)
Variable titration
DeGold PLUS	21	12 M	53.8 ± 7.6	79.3 ± 15.9	29.5 ± 4.4	9.8 ± 5.4	9.61% ± 1.69%	196.1 ± 53.4	2 OAD (19) 1 OAD (2)

OAD: Oral anti-diabetes drug; FPG: Fasting plasma glucose; BMI: Body mass index.